Sorafenib
- Generic Name
- Sorafenib
- Brand Names
- Nexavar, Sorafenib Accord
- Drug Type
- Small Molecule
- Chemical Formula
- C21H16ClF3N4O3
- CAS Number
- 284461-73-0
- Unique Ingredient Identifier
- 9ZOQ3TZI87
- Background
Sorafenib is a bi-aryl urea and an oral multikinase inhibitor. It targets cell surface tyrosine kinase receptors and downstream intracellular kinases that are implicated in tumour cell proliferation and tumour angiogenesis. First approved by the FDA and European Commission in 2007 for the treatment of hepatocellular carcinoma, sorafenib is also indicated to ...
- Indication
Sorafenib is indicated for the treatment of unresectable hepatocellular carcinoma and advanced renal cell carcinoma.
In the US, it is also indicated for the treatment of patients with locally recurrent or metastatic, progressive, differentiated thyroid carcinoma that is refractory to radioactive iodine treatment.
- Associated Conditions
- Advanced Renal Cell Carcinoma, Angiosarcoma, Gastrointestinal Stromal Tumor (GIST), Leiomyosarcoma (LMS), Unresectable Hepatocellular Carcinoma (HCC), Progressive, locally recurrent radioactive iodine-refractory Differentiated Thyroid Carcinoma (DTC), Progressive, metastatic radioactive iodine-refractory Differentiated Thyroid Carcinoma (DTC)
- Associated Therapies
- -
Treating Relapsed/Recurrent/Refractory Pediatric Solid Tumors With Sorafenib in Combination With Irinotecan
- First Posted Date
- 2016-04-21
- Last Posted Date
- 2019-09-09
- Lead Sponsor
- Washington University School of Medicine
- Registration Number
- NCT02747537
Mechanism of Sorafenib Resistance in Patients With Advanced Hepatocellular Carcinoma
- First Posted Date
- 2016-04-12
- Last Posted Date
- 2019-08-20
- Lead Sponsor
- King Saud University
- Target Recruit Count
- 40
- Registration Number
- NCT02733809
- Locations
- 🇸🇦
King Saud University Medical City, Riyadh, Saudi Arabia
Filgrastim, Cladribine, Cytarabine, and Mitoxantrone With Sorafenib in Treating Patients With Newly-Diagnosed, Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
- Conditions
- Interventions
- First Posted Date
- 2016-04-05
- Last Posted Date
- 2023-07-05
- Lead Sponsor
- University of Washington
- Target Recruit Count
- 84
- Registration Number
- NCT02728050
- Locations
- 🇺🇸
Fred Hutch/University of Washington Cancer Consortium, Seattle, Washington, United States
Study of SECOX Versus Sorafenib as First-Line Treatment in Patients With Advanced Hepatocellular Carcinoma (HCC)
- Conditions
- Interventions
- First Posted Date
- 2016-03-23
- Last Posted Date
- 2020-04-10
- Lead Sponsor
- The University of Hong Kong
- Target Recruit Count
- 46
- Registration Number
- NCT02716766
- Locations
- 🇭🇰
Queen Mary Hospital, Hong Kong, Hong Kong
Study to Evaluate the Safety and Efficacy of Sorafenib, in Subject With Refractory Solid Tumors
- First Posted Date
- 2016-02-25
- Last Posted Date
- 2019-12-30
- Lead Sponsor
- Samsung Medical Center
- Registration Number
- NCT02691780
- Locations
- 🇰🇷
Samsung Medical Center, Seoul, Seoul, Korea, Republic Of, Korea, Republic of
Metformin Plus Sorafenib for Advanced HCC
- First Posted Date
- 2016-02-03
- Last Posted Date
- 2016-02-03
- Target Recruit Count
- 82
- Registration Number
- NCT02672488
- Locations
- 🇨🇳
Tianjin Medical University Cancer Institute and Hospital, Tianjin, China
Efficacy and Safety of Donafenib in Patients With Advanced Hepatocellular Carcinoma
- First Posted Date
- 2016-01-05
- Last Posted Date
- 2020-01-09
- Lead Sponsor
- Suzhou Zelgen Biopharmaceuticals Co.,Ltd
- Target Recruit Count
- 668
- Registration Number
- NCT02645981
- Locations
- 🇨🇳
West China Hospital Sichuan University, Chengdu, Sichuan, China
🇨🇳The PLA 81 Hospital, Nanjing, Jiangsu, China
Genomics-Based Target Therapy for Children With Relapsed or Refractory Malignancy
- Conditions
- Interventions
- First Posted Date
- 2015-12-23
- Last Posted Date
- 2020-03-19
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 90
- Registration Number
- NCT02638428
- Locations
- 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of
Sorafenib Administered Using a High-dose, Pulsatile Regimen: a Phase I Exposure Escalation Study
- First Posted Date
- 2015-12-21
- Last Posted Date
- 2018-10-22
- Lead Sponsor
- Amsterdam UMC, location VUmc
- Target Recruit Count
- 17
- Registration Number
- NCT02636426
- Locations
- 🇳🇱
VU University Medical Center, Amsterdam, Noord-Holland, Netherlands
A Study to Compare Tivozanib Hydrochloride to Sorafenib in Participants With Refractory Advanced Renal Cell Carcinoma (RCC)
- Conditions
- Interventions
- First Posted Date
- 2015-12-11
- Last Posted Date
- 2023-07-18
- Lead Sponsor
- AVEO Pharmaceuticals, Inc.
- Target Recruit Count
- 350
- Registration Number
- NCT02627963
- Locations
- 🇨🇦
Dr. Leon Richard Oncology Centre, Moncton, New Brunswick, Canada
🇺🇸New York Oncology Hematology, PC, Albany, New York, United States
🇺🇸Beth Israel Deaconess Medical Center, Boston, Massachusetts, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.